Decentralized clinical trial pioneer Medable unveiled an intelligent automation technology at the JP Morgan Health Care Conference, claiming it can slash standard trial build timelines by at least 50%. This development hinges around electronic clinical outcomes assessment (eCOA) — a common bottleneck in trial startups.
“We’ve used AI to essentially take a protocol and translate that into a mobile application that is running on a patient’s phone,” said Dr. Michelle Longmire, CEO of the company in a recent interview. “The app can partner with patients in their health journey, asking them the right questions at the right times to understand how they’re doing with their clinical trial intervention.”
The AI in question involves the use of large language models for complex task automation and workflow orchestrations.
Medable notes that prominent Big Pharma companies are using the automation technology to cut weeks off build times. “AI has sol…